Premium
Development of specificity and stereoselectivity of rat brain dopamine receptors
Author(s) -
Miller Jeannette C.,
Friedhoff Arnold J.
Publication year - 1986
Publication title -
international journal of developmental neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.761
H-Index - 88
eISSN - 1873-474X
pISSN - 0736-5748
DOI - 10.1016/0736-5748(86)90012-2
Subject(s) - dopamine , dopaminergic , haloperidol , dopamine receptor d2 , striatum , dopamine receptor , medicine , endocrinology , spiperone , chemistry , biology , pharmacology
Abstract Prenatal exposure to the neuroleptic haloperidol has been reported to produce an enduring decrement in the number of dopamine D 2 receptors in rat striatum and a persistent diminution of a dopamine dependent behavior, stereotypy. 17 The ontogeny of rat brain dopamine binding sites has been studied in terms of the kinetic properties and phenotypic specificity in rat fetal brain through early postnatal development. Sites showing some properties of the D 2 binding site can be found prior to gestational day (GD) 18, can be labeled with [ 3 H]dopamine or [ 3 H]spiroperidol and can he displaced with dopaminergic agonists and antagonists. 5 Saturation kinetics for specific [ 3 H]spiroperidol has previously been found to occur on or about GD 18. 1.5 It is of interest that the critical period for the prenatal effect of haloperidol to reduce striatal D 2 binding sites. CD's 15–18. 18 coincides with the period during which dopamine binding sites lack true specificity, but can be labeled with dopaminergic ligands. In these experiments the development of stereoselectivity of brain dopamine binding sites has been examined. When rat mothers were given either the neuroleptic (+)‐butaclamol or its therapeutically inactive isomer (−)‐butaclamol during the critical period CD's 15–18. the number of [ 3 H]spiroperidol binding sites in striata of offspring was significantly reduced by both stereoisomers. This is in marked contrast to the postnatal treatment effect by a neuroleptic in which upregulation of striatal D 2 binding sites occurs only by treatment with the therapeutically active isomer (+)‐butaclamol. In vitro studies of the direct effect of the stereoisomers of butaclamol indicate that the recognition sites detected during fetal brain development with [ 3 H]spiroperidol do not distinguish between the isomers of butaclamol. The point at which stereoselectivity is apparent also appears to be the point at which the prenatal neuroleptic effect is no longer operative and the mature response to increase the number of dopamine binding sites occurs.